AstraZeneca

DRUG PRODUCT		**Synopsis**	(FOR NATIONAL AUTHORITY USE ONLY)
DRUG SUBSTANCE	H 199/18	REFERRING TO PART	
DOCUMENT NO.	SH-QBE-0058	OF THE DOSSIER	
VERSION NO.	01		
STUDY CODE	SH-QBE-0058		
DATE	28 January, 2000		

A comparative study on 40 mg H 199/18 and 40 mg pantoprazole with regard to effect on 24-hour intragastric pH in patients with symptomatic gastroesophageal reflux disease

STUDY CENTRE

Single-centre study

PUBLICATION (REFERENCE)

This section is not applicable.

STUDY PERIOD

- DATE OF FIRST PATIENT ENROLLED 5 October, 1999
- DATE OF LAST PATIENT COMPLETED 17 November, 1999

PHASE OF DEVELOPMENT

Therapeutic confirmatory

OBJECTIVES

The primary objective was to compare the percentage of time with an intragastric pH>4 on days 1 and 5 of 40 mg H 199/18 and 40 mg pantoprazole after repeated once-daily administration in patients with symptomatic gastroesophageal reflux disease.

The secondary objective was to compare the percentage of time with an intragastric pH>3 on days 1 and 5 of 40 mg H 199/18 and 40 mg pantoprazole after repeated once-daily administration in patients with symptomatic gastroesophageal reflux disease.

STUDY DESIGN

Open, randomised, two-way cross-over study

DIAGNOSIS AND MAIN CRITERIA FOR INCLUSION/EXCLUSION

Patients with symptomatic gastroesophageal reflux disease (GERD).

TEST PRODUCT, BATCH NUMBER, DOSAGE AND MODE OF ADMINISTRATION

H 199/18 capsule 40 mg, batch no. H 1222-04-01-08, oral dose of 40 mg o.m.

COMPARATOR PRODUCT, BATCH NUMBER, DOSAGE AND MODE OF ADMINISTRATION

Pantoprazole (Pantoloc®) tablet 40 mg, batch no. H 1131-04-01-02, oral dose of 40 mg o.m.

DURATION OF TREATMENT

Two periods of 5 days separated by a wash-out period of at least 14 days

MAIN MEASUREMENTS AND VARIABLES:

- PHARMACOKINETIC

  This section is not applicable.

- PHARMACODYNAMIC

  The percentage of time with intragastric pH>4 and intragastric pH>3 for 24 hours.

- SAFETY

  Adverse Events (AE), laboratory assessments, ECG and physical examination.

METHODS FOR DATA EVALUATION

The percentage of time with intragastric pH>4 and percentage of time with intragastric pH>3 during the 24-hour period following drug administration were analysed separately, using a mixed model ANOVA with fixed effects for period, sequence and treatment and a random effect for patient within sequence. The mean for each treatment and the mean treatment difference were estimated with 95% confidence intervals.

PATIENTS

	Total
No. planned	32
No. randomised and treated	32
Males/Females	19/13
Mean age (range)	27.5 years (21-53)
No. analysed for pharmacodynamics	31
No. analysed for safety	32
No. completed	30

SUMMARY

- PHARMACOKINETIC RESULTS

  This section is not applicable.

- PHARMACODYNAMIC RESULTS

  The estimated difference in percentage of time with intragastric pH>4 on day 1 between 40 mg H 199/18 and 40 mg pantoprazole was 21% (95% CI; 15% to 27%). On day 5 the estimated difference was 22% (95% CI; 19% to 26%). For pH>3, the estimated difference on day 1 was 21% (95% CI; 15% to 27%), and on day 5 it was 17% (CI; 14% to 21%).

- SAFETY RESULTS

  The adverse events reported were of mild to moderate intensity. The reporting frequency was similar between the two treatment groups.